Barbara Duci (Evolva Holding SA (SIX: EVE))

Duci, Barbara (Evolva 202103 Head of Investor + Corporate Relations)

	Organisation	Evolva Holding SA (SIX: EVE)
	Group	Lallemand (Group)
	Product	food ingredient
	Product 2	industrial biotechnology

Evolva S.A.. (3/24/21). "Press Release: Evolva Announces New Chief Financial Officer". Reinach.

Evolva (SIX:EVE) announced today that Carsten Däweritz has been appointed Chief Financial Officer. He will report to Oliver Walker, CEO of Evolva, and will join the Management Team of the company effective April 16, 2021.

Oliver Walker, CEO of Evolva, said: «I'm pleased that Carsten has accepted the role of CFO at Evolva. Carsten has extensive leadership experience in financial positions. He has our full support and confidence as we continue to grow the business.»

Regarding his appointment, Carsten said: «I'm honored and excited to be given the opportunity to join one of the promising biotech businesses.»

Carsten Däweritz has broad financial experience in the pharma and biotech industry. Before joining Evolva, Carsten spent almost 20 years at Lonza in a variety of financial leadership positions. Most recently, he was Global Head Controlling of the Consumer Health & Nutrition Business at Lonza.

Carsten is a Swiss and German citizen. He has a Bachelor in Mathematics and holds a Master in Business Administration from the University of Münster, Germany.

About Evolva

Evolva is a Swiss biotech company focused on the research, development and commercialization of ingredients based on nature. We have leading businesses in Flavors and Fragrances, Health Ingredients and Health Protection. Evolva's employees, half of which are women, are dedicated to make the best products that can contribute to health, wellbeing and sensory enjoyment. Find out more at www.evolva.com.

For Evolva multi media content, please visit: https://evolva.com/multimedia-library/.

Disclaimer

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

Contact

Barbara Duci
Head of Investor and Corporate Relations
+41 61 485 2003
+41 79 739 2636
[email protected]

Record changed: 2024-07-17

Picture EBD Group Biotech Showcase 2025 San Francisco BTS25 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

» top